De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer

被引：0
|
作者：
Lorena Gonzalez
Joanne Mortimer
Laura Kruper
机构：
[1] City of Hope National Medical Center,Department of Surgery, Division of Breast Surgery
[2] City of Hope National Medical Center,Department of Medical Oncology
来源：
Current Breast Cancer Reports | 2021年 / 13卷
关键词：
Systemic chemotherapy; Her2+ breast cancer; Triple-negative breast cancer; T1a,bN0;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：151 / 156
页数：5
相关论文
共 50 条
  • [41] Impact of neoadjuvant systemic therapies on axillary response in early-stage triple-negative breast cancer
    Kook, Y.
    Minji, L.
    Moon, S.
    Ho, B. Seung
    Bae, S. J.
    Jeong, J.
    Ahn, S. G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1408 - S1408
  • [42] Prognostic value of systemic inflammatory response in early-stage triple-negative breast cancer.
    Ovcaricek, Tanja
    Matos, Erika
    Auprih, Masa
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?
    Maltoni, Roberta
    Palleschi, Michela
    Altini, Mattia
    Massa, Ilaria
    Balzi, William
    Ravaioli, Sara
    Tumedei, Maria Maddalena
    Rocca, Andrea
    Bravaccini, Sara
    CLINICAL BREAST CANCER, 2020, 20 (04) : 359 - 360
  • [44] Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
    Gandhi, Shipra
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (09):
  • [45] Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer
    Gorshein, Elan
    Klein, Paula
    Boolbol, Susan K.
    Shao, Theresa
    CLINICAL BREAST CANCER, 2014, 14 (05) : 309 - 314
  • [46] The evolution in management of patients with subcentimeter, node-negative, triple-negative breast cancer Discussion
    Edney, James
    Wolfe, Emily
    Mangram, Alicia
    Chagpar, Anees
    AMERICAN JOURNAL OF SURGERY, 2013, 206 (06): : 892 - 893
  • [47] High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative early breast cancer patients
    Vaccaro, A.
    Ciancola, F.
    Pizzuti, L.
    Sperduti, I.
    Moscetti, L.
    Vici, P.
    Longo, F.
    Ruggeri, E.
    Di Seri, M.
    Giampaolo, M. A.
    Gamucci, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
    Maria Jose Bueno
    Silvana Mouron
    Eduardo Caleiras
    Mario Martínez
    Luis Manso
    Ramón Colomer
    Miguel Quintela-Fandino
    Clinical and Translational Oncology, 2024, 26 : 1273 - 1279
  • [49] Distribution of PD-L1, TROP2 and HER2-"lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation
    Bueno, Maria Jose
    Mouron, Silvana
    Caleiras, Eduardo
    Martinez, Mario
    Manso, Luis
    Colomer, Ramon
    Quintela-Fandino, Miguel
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (05): : 1273 - 1279
  • [50] Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer
    Hao, Xiaopeng
    Gao, Xianqi
    Yin, Shanshan
    Jiang, Zefei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
12345